Amundi Increases Stock Position in Bruker Corporation $BRKR

Key Points

• Amundi increased its Bruker stake by 244.2% in the first quarter to 62,611 shares valued at $2.26 million. Institutional investors collectively own 79.52% of the company.
• Bruker’s quarterly adjusted EPS of $0.49 exceeded the $0.38 consensus, while revenue rose 5.2% year over year. However, revenue of $838.5 million missed estimates of $853.6 million, contributing to investor concerns about demand and weak growth in its primary market.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and $56.64 target price, though Citigroup cut its target to $53 and maintained a “neutral” rating. Shares opened at $51.27, below the consensus target.

Amundi lifted its position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 244.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,611 shares of the medical research company's stock after buying an additional 44,421 shares during the period. Amundi's holdings in Bruker were worth $2,261,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Orbis Allan Gray Ltd lifted its stake in shares of Bruker by 5.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock valued at $702,256,000 after purchasing an additional 761,258 shares in the last quarter. State Street Corp increased its position in Bruker by 2.5% during the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock worth $180,700,000 after purchasing an additional 91,706 shares in the last quarter. AQR Capital Management LLC increased its position in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. Sculptor Capital LP raised its holdings in Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock valued at $118,112,000 after buying an additional 270,000 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock valued at $111,488,000 after buying an additional 2,289,269 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Zacks upgraded Bruker from “hold” to “strong-buy,” providing a favorable analyst signal that could support investor sentiment. Zacks.com
• Positive Sentiment: Management highlighted margin strength during the second-quarter earnings call. Bruker also reported adjusted earnings of $0.49 per share, exceeding the $0.38 analyst consensus, while revenue increased 5.2% year over year. Bruker Corporation Earnings Call Highlights Margin Strength
• Neutral Sentiment: Citigroup lowered its price target from $60 to $53 and maintained a “neutral” rating. The revised target implies limited upside from the current trading level, signaling reduced confidence in near-term appreciation. Benzinga
• Negative Sentiment: Second-quarter revenue of $838.5 million fell short of the $853.6 million consensus estimate. The sales miss triggered a sharp selloff, despite the earnings beat, as investors focused on weaker-than-expected demand. Bruker Q2 2026 Earnings
• Negative Sentiment: Analysts continue to cite weak growth in Bruker’s primary market as a significant overhang, raising concerns about the pace of future revenue expansion. Weak Growth in Bruker’s Primary Market

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BRKR. Wall Street Zen upgraded Bruker from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Zacks Research upgraded Bruker from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. Citigroup decreased their target price on Bruker from $60.00 to $53.00 and set a "neutral" rating for the company in a research report on Wednesday. Leerink Partners increased their target price on Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded Bruker from a "sell (d)" rating to a "sell (d+)" rating in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.64.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $51.27 on Friday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The business has a 50 day moving average price of $58.61 and a two-hundred day moving average price of $46.75. The company has a quick ratio of 0.72, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm has a market cap of $7.80 billion, a PE ratio of -73.24, a price-to-earnings-growth ratio of 1.60 and a beta of 1.28.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the company posted $0.32 EPS. Bruker's quarterly revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, June 22nd. Bruker's dividend payout ratio is -83.33%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source